Patents
Literature
2 results about "Cefotaxime Sodium" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
A long-acting and stable cefotaxime sodium preparation, its preparation method and application
The application discloses a long-acting and stable drug-releasing cefotaxime sodium preparation and a preparation method and application thereof, relates to the technical field of drug synthesis, and the cefotaxime sodium preparation comprises cefotaxime sodium tablet crystals, and a slow-release carrier is coated outside the cefotaxime sodium tablet crystals; the slow-release carrier has a three-level structure, comprising a phospholipid coating layer coated on the surface of the cefotaxime sodium tablet crystals, a mesoporous silica shell layer coated on the surface of the phospholipid coating layer, and a temperature-sensitive hydrogel network layer coated on the surface of the mesoporous silica shell layer. The cefotaxime sodium preparation has the properties of rapid effect, super-long-acting and stable drug-releasing and high stability, and the preparation process flow is simple, and the control condition is mild.
Owner:CHENGDU JINGFU PHARM TECH CO LTD +1
Use of a tar a inhibitor in the manufacture of an antibacterial potentiator for enhancing the efficacy of a beta-lactam antibiotic against a methicillin-resistant staphylococcus aureus infection
This invention relates to the field of biomedical technology, and in particular to the application of TarA inhibitors in the preparation of antibacterial potentiators for enhancing the efficacy of β-lactam antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) infections. Through virtual screening, target validation, and in vitro and in vivo pharmacodynamic experiments, this invention confirms that the natural product norzelamin is an effective TarA inhibitor and antibacterial potentiator. Experiments show that norzelamin has a synergistic effect when used in combination with various β-lactam antibiotics. In a mouse model of MRSA-infected pneumonia, the combination of norzelamin and cefotaxime sodium significantly reduced pulmonary bacterial load, alleviated systemic inflammatory response, and improved lung tissue pathological damage compared to monotherapy. This invention provides a novel synergistic treatment strategy and candidate compound for overcoming MRSA resistance in clinical practice, and has significant development value and application prospects.
Owner:HUAZHONG AGRI UNIV